AKBA Akebia Therapeutics Inc

Price (delayed)

$2.865

Market cap

$458.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.74

Enterprise value

$325.76M

Highlights
The company's quick ratio has surged by 73% YoY and by 13% QoQ
The company's gross margin has shrunk by 128% YoY
AKBA's gross profit has dropped by 121% year-on-year

Key stats

What are the main financial stats of AKBA
Market
Shares outstanding
160.12M
Market cap
$458.73M
Enterprise value
$325.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.06
Price to sales (P/S)
1.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.26
Earnings
Revenue
$259.13M
EBIT
-$380.59M
EBITDA
-$348.98M
Free cash flow
-$91.92M
Per share
EPS
-$2.74
Free cash flow per share
-$0.6
Book value per share
$1.39
Revenue per share
$1.68
TBVPS
$2.85
Balance sheet
Total assets
$628.7M
Total liabilities
$414.81M
Debt
$119.79M
Equity
$213.89M
Working capital
$192.34M
Liquidity
Debt to equity
0.56
Current ratio
2.11
Quick ratio
1.78
Net debt/EBITDA
0.38
Margins
EBITDA margin
-134.7%
Gross margin
-16.9%
Net margin
-151.4%
Operating margin
-147.5%
Efficiency
Return on assets
-58.2%
Return on equity
-136.5%
Return on invested capital
-219.2%
Return on capital employed
-83.5%
Return on sales
-146.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
15.52%
1 week
13.69%
1 month
-22.78%
1 year
-74.3%
YTD
2.32%
QTD
-24.41%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$259.13M
Gross profit
-$43.67M
Operating income
-$382.25M
Net income
-$392.29M
Gross margin
-16.9%
Net margin
-151.4%
The company's gross margin has shrunk by 128% YoY
AKBA's gross profit has dropped by 121% year-on-year
AKBA's net margin has dropped by 98% year-on-year and by 17% since the previous quarter
The operating margin has plunged by 92% YoY and by 16% from the previous quarter

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
2.06
P/S
1.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.26
Akebia Therapeutics's EPS has decreased by 24% YoY
AKBA's P/B is 54% below its 5-year quarterly average of 3.9 and 29% below its last 4 quarters average of 2.5
The equity is down by 46% year-on-year and by 14% since the previous quarter
The price to sales (P/S) is 92% less than the 5-year quarterly average of 18.2 and 41% less than the last 4 quarters average of 2.5
Akebia Therapeutics's revenue has decreased by 26% YoY and by 12% QoQ

Efficiency

How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's return on equity has shrunk by 126% YoY and by 19% QoQ
Akebia Therapeutics's ROS has plunged by 91% YoY and by 16% from the previous quarter
The ROA has plunged by 73% YoY and by 8% from the previous quarter
The return on invested capital has declined by 49% year-on-year and by 15% since the previous quarter

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 52% greater than its total liabilities
The company's quick ratio has surged by 73% YoY and by 13% QoQ
Akebia Therapeutics's current ratio has increased by 33% YoY and by 7% QoQ
AKBA's debt is 44% smaller than its equity
The debt to equity has surged by 115% year-on-year and by 14% since the previous quarter
The equity is down by 46% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.